Needham & Company Reiterates Buy on Dermira (DERM) Following Licensing Agreement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Allergan pays top dollar for 'stepping stones' from neurology to dermatology
September 20, 2016 10:32 AM EDTBy Carl O'Donnell
(Reuters) - Allergan Plc (NYSE: AGN) CEO Brent Saunders calls them "stepping stones" - small, bolt-on acquisitions, as opposed to the mega-deals common in the drug industry. And they're expected to boost dealmaking in sectors ranging from neurology to skin care.
Allergan's agreement on Tuesday to acquire liver drug developer Tobira Therapeutics Inc (NASDAQ: TBRA) for $1.7 billion may seem trivial compared to the proposed $160 billion deal Allergan crafted last year to sell itself to Pfizer Inc (NYSE:... More
